The Human and Mouse Cell Isolation and Phenotyping Core (Core C) will provide services for all four research projects in the University of Utah Molecular Medicine Translational Research Center in Thrombosis (U2M2-TRCT) program. Core C is centrally located and immediately available to all U2M2-TRCT investigators. The core will isolate human and mouse megakaryocytes and platelets for U2M2-TRCT investigators, perform standard in vitro and in vivo platelet function assays, assist with generation, breeding, and maintenance of genetically manipulated mice proposed in projects 1 and 2, and manage mouse models of obesity and diabetes. Core C is led by a group of investigators with strengths and expertise in all of the essential core activities. In order to standardize populations of megakaryocytes and platelets among studies, Core C will isolate and culture megakaryocytes and platelets for all U2M2-TRCT investigators. In this regard. Core C will communicate directly with Core B to ensure seamless isolation of platelets from patients with obesity and diabetes. The Core will also directly communicate with projects 1 and 2 for cell isolation, metabolic phenotyping, and related functional analyses. The Core is equipped with a cell sorter and sterile incubators for isolation and culture of purified human and mouse megakaryocytes and platelets. In addition, the core has equipment for in vitro and in vivo analyses of platelet function and metabolic phenotyping of mice that will be used in projects 1 and 2. Core investigators will also work together to generate, breed, and maintain colonies of mice that are proposed in projects 1 and 2. The U2M2-TRCT program will use the expertise and resources provided by Core C to guide and direct studies proposed in projects 1-4.
Patients with type 2 diabetes, obesity, or the metabolic syndrome are at increased risk for blood clots (thrombosis) caused by cells called platelets. Our studies will determine how metabolic factors in the blood and tissues (the metabolic milieu), such as high glucose and lipids, make platelets more prone to induce thrombosis, providing new insights into the treatment and management of diabetes and obesity.
|Koupenova, Milka; Vitseva, Olga; MacKay, Christopher R et al. (2014) Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis. Blood 124:791-802|
|Schubert, Sebastian; Weyrich, Andrew S; Rowley, Jesse W (2014) A tour through the transcriptional landscape of platelets. Blood 124:493-502|
|Clancy, Lauren; Freedman, Jane E (2014) New paradigms in thrombosis: novel mediators and biomarkers platelet RNA transfer. J Thromb Thrombolysis 37:12-6|
|Freedman, Jane E (2014) Inherited dysfunctional nitric oxide signaling and the pathobiology of atherothrombotic disease. Circ Res 114:1372-3|
|Major, Heather D; Campbell, Robert A; Silver, Robert M et al. (2014) Synthesis of sFlt-1 by platelet-monocyte aggregates contributes to the pathogenesis of preeclampsia. Am J Obstet Gynecol 210:547.e1-7|
|Madden, Jesse L; Drakos, Stavros G; Stehlik, Josef et al. (2014) Baseline red blood cell osmotic fragility does not predict the degree of post-LVAD hemolysis. ASAIO J 60:524-8|
|Shi, Dallas S; Smith, Matthew C P; Campbell, Robert A et al. (2014) Proteasome function is required for platelet production. J Clin Invest 124:3757-66|
|Chen, Karin; Coonrod, Emily M; Kumanovics, Attila et al. (2013) Germline mutations in NFKB2 implicate the noncanonical NF-*B pathway in the pathogenesis of common variable immunodeficiency. Am J Hum Genet 93:812-24|
|Franks, Zechariah; Campbell, Robert A; Vieira de Abreu, Adriana et al. (2013) Methicillin-resistant Staphylococcus aureus-induced thrombo-inflammatory response is reduced with timely antibiotic administration. Thromb Haemost 109:684-95|
|Freedman, Jane E; Tanriverdi, Kahraman (2013) Defining miRNA targets: balancing simplicity with complexity. Circulation 127:2075-7|